ECSP23056223A - Quinolinas y azaquinolinas como inhibidores de cd38 - Google Patents
Quinolinas y azaquinolinas como inhibidores de cd38Info
- Publication number
- ECSP23056223A ECSP23056223A ECSENADI202356223A ECDI202356223A ECSP23056223A EC SP23056223 A ECSP23056223 A EC SP23056223A EC SENADI202356223 A ECSENADI202356223 A EC SENADI202356223A EC DI202356223 A ECDI202356223 A EC DI202356223A EC SP23056223 A ECSP23056223 A EC SP23056223A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- azaquinolines
- quinolines
- cancer
- compounds
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title abstract 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que son inhibidores del CD38 y son útiles para el tratamiento del cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143245P | 2021-01-29 | 2021-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23056223A true ECSP23056223A (es) | 2023-11-30 |
Family
ID=80446310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202356223A ECSP23056223A (es) | 2021-01-29 | 2023-07-25 | Quinolinas y azaquinolinas como inhibidores de cd38 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11952377B2 (es) |
| EP (1) | EP4284511A1 (es) |
| JP (1) | JP2024506814A (es) |
| KR (1) | KR20230141799A (es) |
| CN (1) | CN117580829A (es) |
| AR (1) | AR124718A1 (es) |
| AU (1) | AU2022212035A1 (es) |
| BR (1) | BR112023014898A2 (es) |
| CA (1) | CA3208851A1 (es) |
| CL (1) | CL2023002163A1 (es) |
| CO (1) | CO2023009803A2 (es) |
| CR (1) | CR20230323A (es) |
| DO (1) | DOP2023000142A (es) |
| EC (1) | ECSP23056223A (es) |
| IL (1) | IL304466A (es) |
| PE (1) | PE20232047A1 (es) |
| TW (1) | TW202241418A (es) |
| WO (1) | WO2022165114A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2646020B1 (en) | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
| CA2854447A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| EP2968360B1 (en) | 2013-03-14 | 2021-01-20 | ConverGene LLC | Quinolinone derivatives for the inhibition of bromodomain-containing proteins |
| RU2017121002A (ru) | 2014-12-03 | 2019-01-11 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Ингибиторы CD38 и способы лечения |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| TW202128677A (zh) | 2019-10-30 | 2021-08-01 | 美商米突倍基公司 | Cd38抑制劑 |
| IL297128A (en) | 2020-04-07 | 2022-12-01 | Mitobridge Inc | cd38 inhibitors |
-
2022
- 2022-01-28 WO PCT/US2022/014221 patent/WO2022165114A1/en active Application Filing
- 2022-01-28 US US17/586,939 patent/US11952377B2/en active Active
- 2022-01-28 CR CR20230323A patent/CR20230323A/es unknown
- 2022-01-28 PE PE2023002190A patent/PE20232047A1/es unknown
- 2022-01-28 BR BR112023014898A patent/BR112023014898A2/pt unknown
- 2022-01-28 CA CA3208851A patent/CA3208851A1/en active Pending
- 2022-01-28 AU AU2022212035A patent/AU2022212035A1/en active Pending
- 2022-01-28 JP JP2023544674A patent/JP2024506814A/ja active Pending
- 2022-01-28 AR ARP220100173A patent/AR124718A1/es unknown
- 2022-01-28 CN CN202280022060.6A patent/CN117580829A/zh active Pending
- 2022-01-28 EP EP22704226.4A patent/EP4284511A1/en active Pending
- 2022-01-28 KR KR1020237027359A patent/KR20230141799A/ko unknown
- 2022-01-28 TW TW111103880A patent/TW202241418A/zh unknown
-
2023
- 2023-07-13 IL IL304466A patent/IL304466A/en unknown
- 2023-07-24 CL CL2023002163A patent/CL2023002163A1/es unknown
- 2023-07-25 CO CONC2023/0009803A patent/CO2023009803A2/es unknown
- 2023-07-25 DO DO2023000142A patent/DOP2023000142A/es unknown
- 2023-07-25 EC ECSENADI202356223A patent/ECSP23056223A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022165114A1 (en) | 2022-08-04 |
| CA3208851A1 (en) | 2022-08-04 |
| CL2023002163A1 (es) | 2024-01-05 |
| BR112023014898A2 (pt) | 2023-10-31 |
| EP4284511A1 (en) | 2023-12-06 |
| JP2024506814A (ja) | 2024-02-15 |
| IL304466A (en) | 2023-09-01 |
| TW202241418A (zh) | 2022-11-01 |
| US20220242862A1 (en) | 2022-08-04 |
| CR20230323A (es) | 2023-10-02 |
| CO2023009803A2 (es) | 2023-10-09 |
| DOP2023000142A (es) | 2023-08-31 |
| KR20230141799A (ko) | 2023-10-10 |
| PE20232047A1 (es) | 2023-12-27 |
| AU2022212035A1 (en) | 2023-08-03 |
| AR124718A1 (es) | 2023-04-26 |
| US11952377B2 (en) | 2024-04-09 |
| CN117580829A (zh) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013599A2 (es) | Piridazinonas como inhibidoras de parp7 | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
| CL2020002082A1 (es) | Inhibidores pd-1/pd-l1. | |
| CL2021000355A1 (es) | Inhibidores de ptpn11 | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CO2022004694A2 (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
| CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| CL2019002557A1 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| BR112022001291A2 (pt) | Amidas heterobicíclicas como inibidores de cd38 | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| ECSP23056223A (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). |